Lyell Immunopharma (NASDAQ:LYEL) Releases Earnings Results, Beats Expectations By $0.10 EPS

Posted by on Aug 8th, 2026

Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($1.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.02) by $0.10, reports. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 87.60%. The company had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.01 million.

Lyell Immunopharma Price Performance

NASDAQ:LYEL traded up $0.50 during mid-day trading on Friday, hitting $14.71. 110,955 shares of the company’s stock were exchanged, compared to its average volume of 170,417. The company has a market cap of $360.39 million, a PE ratio of -1.15 and a beta of -0.04. Lyell Immunopharma has a one year low of $9.28 and a one year high of $45.00. The business has a fifty day moving average price of $13.44 and a 200 day moving average price of $19.01.

Hedge Funds Weigh In On Lyell Immunopharma

Large investors have recently made changes to their positions in the business. Invesco Ltd. purchased a new position in shares of Lyell Immunopharma during the fourth quarter valued at approximately $3,036,000. ExodusPoint Capital Management LP purchased a new stake in shares of Lyell Immunopharma in the 4th quarter worth approximately $262,000. Barclays PLC grew its stake in shares of Lyell Immunopharma by 1,239.5% in the 4th quarter. Barclays PLC now owns 15,967 shares of the company’s stock worth $491,000 after buying an additional 14,775 shares during the last quarter. Marshall Wace LLP bought a new position in Lyell Immunopharma during the 4th quarter valued at approximately $2,257,000. Finally, Charles Schwab Investment Management Inc. increased its position in Lyell Immunopharma by 7.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 85,423 shares of the company’s stock valued at $2,629,000 after buying an additional 5,913 shares in the last quarter. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Zacks Research upgraded shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Robert W. Baird set a $49.00 target price on Lyell Immunopharma and gave the company an “outperform” rating in a research note on Thursday, April 30th. Stifel Nicolaus initiated coverage on Lyell Immunopharma in a research report on Thursday. They set a “buy” rating and a $36.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of Lyell Immunopharma in a research note on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Get Our Latest Analysis on Lyell Immunopharma

Lyell Immunopharma Company Profile

(Get Free Report)

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.

Featured Stories

Earnings History for Lyell Immunopharma (NASDAQ:LYEL)

Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.